Wuxi Bio announced that the company noted that a procedural ...
Wuxi Bio announced that the company noted that a procedural hearing about a revised draft bill was held by the U.S. Senate. Wuxi Bio's share price extended furtherdecline to 21%in HK in the afternoon session. The company reiterated that it is not a subsidiary of WUXI Apptec and does not have a human genomics business, nor does it collect human genomic data in any of its businesses.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
102884128 : US senate up to. doing business in US also not easy.
Smart603 102884128 : They are all sucker